Combating disease and aging by reversing age

199 Biotechnologies is pioneering innovative therapeutic strategies that focus on reprogramming the epigenome to combat cancer, particularly emphasizing brain cancer, which presents significant treatment challenges. Their first-in-class approach targets the epigenetic alterations that drive tumor growth and resistance to conventional therapies. By inducing natural senescent apoptosis in cancer cells, their technology aims to reverse malignant cellular programming while sparing healthy tissue. This comprehensive strategy addresses multiple aspects of cancer biology, including tumor growth, invasion, and the targeting of cancer stem cells, thereby offering a more effective alternative to traditional treatments that primarily focus on cell death.

The company employs advanced delivery platforms, including mRNA and cell therapy, to enhance the efficacy of their reprogramming therapies. Their mRNA platform utilizes novel delivery vehicles to ensure precise targeting of cancer cells, minimizing off-target effects. Additionally, their organ-on-a-chip technology allows for in vitro simulation of human organ systems, facilitating the study of epigenetic rejuvenation effects in a controlled environment. This innovative approach not only accelerates the understanding of their therapies but also supports high-throughput screening and detailed mechanistic studies, positioning 199 Biotechnologies at the forefront of cancer treatment advancements.

United Kingdom

199 Biotechnologies is an early-stage company developing first-in-class therapies that target the fundamental mechanisms of aging, with the goal of transforming the landscape of age-related disease treatment and prevention.

199 Biotechnologies

Company Details